FDA Tosses Par Pharma's Anti-Generic Bid, Vows FTC Referral

By Adam Lidgett (December 16, 2021, 8:45 PM EST) -- The U.S. Food and Drug Administration has shot down Par Pharmaceutical's bid to keep a rival generic of its flagship drug off the market, even going so far as to say it intends to send the issue to the Federal Trade Commission.

The FDA on Wednesday denied a petition from Par, a unit of Endo Pharmaceuticals, that the agency not approve an abbreviated new drug application for a generic version of its blood pressure drug Vasostrict.

The FDA said the petition "appears to have been submitted for the primary purpose" of simply delaying approval of the Eagle Pharmaceuticals generic and "fails to...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!